Skip to main content

Advertisement

SpringerLink
Log in

Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI

  • Gastrointestinal
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

Typical MRI findings for gastro-intestinal stromal tumours (GIST) under treatment with imatinib were evaluated. MRI was performed in 45 patients (25 responders, 20 non-responders) with metastatic or locally advanced, unresectable GIST. Target lesions were selected and re-evaluated after 2, 4, and 6 months of therapy with imatinib. The target tumour response (TTR) was classified according to RECIST criteria. TTR, signal intensity in the centre and border of the lesion and the presence and the extension of a hypervascular rim were analysed. The mean diameter of the marker lesions decreased significantly (P<0.001) from 7.1±2.6 cm to 5.9±2.3 cm after 6 months. Accuracy of RECIST criteria was 51%, 69% and 73% on MRI 2, 4 and 6 months for response assessment. In addition, responders had higher signal-to-noise ratios on T2-w images after 2 months (P<0.05) and a decrease of vascularised areas in the lesion 4 and 6 months after treatment (each P<0.01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, Wangberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89:460–464

    PubMed  Google Scholar 

  2. Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D (2005) Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 9:1–142

    Google Scholar 

  3. Shojaku H, Futatsuya R, Seto H, Tajika S, Matsunou H (1997) Malignant gastrointestinal stromal tumor of the small intestine: radiologic-pathologic correlation. Radiat Med 15:189–192

    PubMed  Google Scholar 

  4. Maki RG (2004) Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Curr Treat Options Gastroenterol 7:13–17

    PubMed  Google Scholar 

  5. Joensuu H, Roberts PJ, Sarlomo Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    PubMed  Google Scholar 

  6. Joensuu H, Dimitrijevic S (2001) Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33:451–455

    PubMed  Google Scholar 

  7. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) European organisation for research and treatment of cancer soft tissue and bone sarcoma group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft tissue and bone sarcoma group. Eur J Cancer 38 Suppl 5:S83–S87

    PubMed  Google Scholar 

  8. Andersson J, Sjogren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160:15–22

    PubMed  Google Scholar 

  9. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC (2003) Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226:527–532

    PubMed  Google Scholar 

  10. Ghanem N, Altehoefer C, Furtwangler A, Winterer J, Schafer O, Springer O, Kotter E, Langer M (2003) Computed tomography in gastrointestinal stromal tumors. Eur Radiol 13:1669–1678

    PubMed  Google Scholar 

  11. Kim HC, Lee JM, Kim KW, Park SH, Kim SH, Lee JY, Han JK, Choi BI (2004) Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. AJR Am J Roentgenol 183:893–898

    PubMed  Google Scholar 

  12. Tateishi U, Hasegawa T, Satake M, Moriyama N (2003) Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr 27:792–798

    PubMed  Google Scholar 

  13. Chen MYM, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 179:1059–1062

    PubMed  Google Scholar 

  14. Sigmund G, Buitrago-Tellez CH, Torhorst J, Steinbrich W (2000) Radiology of gastrointestinal stromal tumors (GIST) and a case of carney syndrome. Fortschr Rontgenstr 172:287–294

    Article  Google Scholar 

  15. Tervahartiala P, Halavaara J (1998) Radiology of GIST. Gastrointestinal stromal tumours. Ann Chir Gynaecol 87:291–292

    PubMed  Google Scholar 

  16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    PubMed  Google Scholar 

  17. Hasegawa S, Semelka RC, Noone TC, Woosley JT, Marcos HB, Kenney PJ, Siegelman ES (1998) Gastric stromal sarcomas: correlation of MR imaging and histopathologic findings in nine patients. Radiology 208:591–595

    PubMed  Google Scholar 

  18. Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P (2004) Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 57:215–217

    Article  PubMed  Google Scholar 

  19. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5:S60–S65

    Google Scholar 

  20. Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:3357–3365

    Google Scholar 

  21. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D (2004) The role of (18)F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21

    PubMed  Google Scholar 

  22. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020

    Article  PubMed  Google Scholar 

  23. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655–664

    PubMed  Google Scholar 

  24. Jost D, Stroszczynski C, Chmelik P, Gaffke G, Schlecht I, Pink D, Reichardt P, Schneider U, Hohenberger P, Felix R (2003) Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib. Fortschr Rontgenstr 175:791–798

    Article  Google Scholar 

  25. van den Abbeele AD, Badawi RD, Cliche JP et al (2002) Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT [abstract]. Radiology 225 (Suppl):424

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Strahlenheilkunde, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

    Christian Stroszczynski, Dominik Jost, Petra Chmelik, Gunnar Gaffke & Roland Felix

  2. Klinik für Hämatologie, Onkologie und Tumorimmunologie CCB Robert-Roessle-Klinik, im Helios-Klinikum-Berlin, Berlin, Germany

    Peter Reichardt & Albrecht Kretzschmar

  3. Institut für Pathologie CCB, Berlin, Germany

    Ulrike Schneider

  4. Klinik für Chirurgie und Chirurgische Onkologie CCB Robert-Roessle-Klinik, im Helios-Klinikum-Berlin, Berlin, Germany

    Peter Hohenberger

  5. Chirurgische Klinik am Universitätsklinikum Mannheim, Klinikum Mannheim, Mannheim, Germany

    Peter Hohenberger

Authors
  1. Christian Stroszczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominik Jost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Reichardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Petra Chmelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gunnar Gaffke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Albrecht Kretzschmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulrike Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roland Felix
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peter Hohenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Stroszczynski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stroszczynski, C., Jost, D., Reichardt, P. et al. Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 15, 2448–2456 (2005). https://doi.org/10.1007/s00330-005-2867-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-005-2867-x

Keywords

Search

Navigation